Clinical Trial Update: Lean Body Mass as a Determinant of Docetaxel Pharmacokinetics and Toxicity

View source ↗

Summary

A completed clinical trial evaluating whether lean body mass influences the pharmacokinetics and toxicity of docetaxel. The study involved patients with breast …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Castration-resistant Prostate Cancer

Drugs mentioned

• Taxotere (docetaxel)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Breast Cancer, Metastatic Castration-resistant Prostate Carcinoma | Status: COMPLETED